AtriCure, Inc. (ATRC) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
AtriCure’s revenue went from $155M in fiscal 2016 to $535M in fiscal 2025, growth of about 14.7% a year.
Net income in fiscal 2025 was -$11M, a net margin of -2.1%; the best year in this period was 2021 with $50M.
Over the twelve months to September 30, 2026, revenue was $590M and net income $15M.
Free cash flow was $48M in fiscal 2025 and positive in 2 of the 10 years shown.
The diluted share count rose 51% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $590M | $535M | $465M | $399M | $330M | $274M | $207M | $231M | $202M | $175M | $155M |
| Gross profit | $453M | $401M | $348M | $300M | $246M | $206M | $149M | $170M | $147M | $126M | $111M |
| Operating income | $17M | -$9M | -$40M | -$27M | -$43M | $55M | -$44M | -$33M | -$17M | -$25M | -$31M |
| Net income | $15M | -$11M | -$45M | -$30M | -$46M | $50M | -$48M | -$35M | -$21M | -$27M | -$33M |
| EPS (diluted) | $0.30 | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 | $-1.14 | $-0.94 | $-0.62 | $-0.83 | $-1.05 |
| R&D | $107M | $99M | $96M | $74M | $57M | $49M | $43M | $41M | $35M | $34M | $36M |
| Revenue growth | — | +14.9% | +16.6% | +20.8% | +20.4% | +32.8% | −10.5% | +14.5% | +15.4% | +12.6% | +19.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $69M | $57M | $12M | $4M | -$22M | -$14M | -$20M | -$16M | -$4M | -$9M | -$15M |
| Capital spending | -$16M | -$9M | -$11M | -$12M | -$17M | -$10M | -$5M | -$12M | -$6M | -$6M | -$8M |
| Free cash flow | $53M | $48M | $745000 | -$8M | -$39M | -$24M | -$25M | -$28M | -$10M | -$15M | -$23M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $47M | $45M | $40M | $36M | $29M | $28M | $23M | $18M | $16M | $15M | $12M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $167M | $123M | $137M | $121M | $119M | $244M | $82M | $124M | $34M | $44M |
| Debt | — | $69M | $71M | $68M | $67M | $65M | $62M | $64M | $53M | $37M | $39M |
| Equity | — | $492M | $461M | $466M | $457M | $484M | $412M | $247M | $249M | $161M | $168M |
| Total assets | — | $654M | $609M | $614M | $585M | $615M | $715M | $558M | $357M | $268M | $276M |
| Shares (diluted) | 50M | 48M | 47M | 46M | 46M | 46M | 42M | 38M | 34M | 32M | 32M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 76.7% | 75.0% | 74.7% | 75.2% | 74.4% | 75.0% | 72.3% | 73.8% | 73.0% | 72.2% | 71.6% |
| Operating margin | 2.9% | -1.8% | -8.6% | -6.7% | -12.9% | 20.1% | -21.4% | -14.3% | -8.5% | -14.3% | -20.1% |
| Net margin | 2.5% | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% | -15.2% | -10.5% | -15.4% | -21.5% |
| FCF margin | 9.0% | 9.0% | 0.2% | -1.9% | -11.8% | -8.6% | -12.2% | -12.1% | -5.1% | -8.8% | -14.7% |
| ROIC | — | -1.3% | -5.9% | -4.0% | -6.4% | 10.0% | -7.4% | -8.4% | -4.5% | -9.9% | -11.9% |
| ROE | — | -2.3% | -9.7% | -6.5% | -10.2% | 10.4% | -11.7% | -14.2% | -8.5% | -16.7% | -19.8% |
Frequently asked questions
What is AtriCure’s annual revenue?
$535M in fiscal 2025 and $590M over the twelve months to September 30, 2026.
How much profit does AtriCure make?
Net income was -$11M in fiscal 2025 (net margin -2.1%).
Is AtriCure’s revenue growing?
Yes: revenue rose 14.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.